Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research
- PMID: 24339912
- PMCID: PMC3855252
- DOI: 10.1371/journal.pone.0081234
Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research
Abstract
Objectives: While various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients.
Methods: A literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy.
Results: High methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1β, IL-6, TNF-α levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these confounders included subjects' cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety, depression and fatigue.
Conclusion: Although existing studies observed cognitive impairment and cytokine dysregulation in patients who receive chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize future studies of this subject matter.
Conflict of interest statement
Figures


Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419291 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
Cited by
-
Chemotherapy-induced cognitive impairment: focus on the intersection of oxidative stress and TNFα.Cell Mol Life Sci. 2021 Oct;78(19-20):6533-6540. doi: 10.1007/s00018-021-03925-4. Epub 2021 Aug 23. Cell Mol Life Sci. 2021. PMID: 34424346 Free PMC article. Review.
-
Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type.PLoS One. 2017 Mar 7;12(3):e0171724. doi: 10.1371/journal.pone.0171724. eCollection 2017. PLoS One. 2017. PMID: 28267750 Free PMC article.
-
Neuropathological Effects of Chemotherapeutic Drugs.ACS Chem Neurosci. 2021 Aug 18;12(16):3038-3048. doi: 10.1021/acschemneuro.1c00338. Epub 2021 Aug 9. ACS Chem Neurosci. 2021. PMID: 34370453 Free PMC article.
-
Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review.Support Care Cancer. 2016 Jan;24(1):481-497. doi: 10.1007/s00520-015-2927-y. Epub 2015 Sep 29. Support Care Cancer. 2016. PMID: 26416490
-
Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study.Croat Med J. 2019 Apr 30;60(2):166-173. doi: 10.3325/cmj.2019.60.166. Croat Med J. 2019. PMID: 31044590 Free PMC article.
References
-
- Cheung YT, Maung Shwe HG, Tan YP, Fan GKT, Ng RCH, et al. (2012) Cognitive changes in multiethnic Asian breast cancer patients: A focus group study. Ann Oncol 23: 2547–2552. - PubMed
-
- Vardy J (2009) Cognitive function in breast cancer survivors. Cancer Treat Res 151: 387–419. - PubMed
-
- Cheung YT, Chui WK, Chan A (2011) Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. Crit Rev Oncol Hematol 83: 99–111. - PubMed
-
- Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. J Clin Nurs 19: 1362–1370. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical